Helix BioPharma's total assets for Q4 2024 were C$1.49M, an increase of 30.04% from the previous quarter. TSE:HBP total liabilities were C$1.58M for the fiscal quarter, a 4.92% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.